New Drug to Reduce the Risk of Preterm BirthAschenbrenner, Diane S. MS, RNAJN, American Journal of Nursing: June 2011 - Volume 111 - Issue 6 - p 24-25 doi: 10.1097/01.NAJ.0000398535.21789.c1 Drug Watch Buy Abstract Author InformationAuthors Article MetricsMetrics Hydroxyprogesterone caproate (Makena) is the first drug approved to prevent preterm labor. Hydroxyprogesterone caproate is given weekly by injection to women who've had at least one premature birth. It's intended for use only in singleton pregnancies. Injection-site reactions are the most common adverse effect; others are hives, nausea, and diarrhea. Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: firstname.lastname@example.org. © 2011 Lippincott Williams & Wilkins, Inc.